Innovative Medicines Initiative (IMI 2)
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.276 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.
IMI was launched in 2008 and currently has 46 ongoing projects, with more in the pipeline. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects
Giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. IMI warmly encourages small and medium-sized enterprises (SMEs), medium-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.
IMI2 Call 8: Next deadlines
Next cut-off date for IMI2 Ebola+ call for proposals: 15/3/2018
IMI2 Call 13 is now open!
• Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• Genome-environment interactions in inflammatory skin disease
• The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• Mitochondrial dysfunction in neurodegeneration
• Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
• A sustainable European induced pluripotent stem cell platform
• Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• Human tumour microenvironment immunoprofiling
• ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
• Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases
Deadline for submission: 28/2/2018
Documents and information: http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13
Webinars for each of the topics: http://www.imi.europa.eu/news-events/events/webinars-imi2-call-13